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Introduction: Phacomatosis pigmentovascularis is a rare congenital condition characterized by vascular
malformation associated with extensive pigmented nevi. Even though it forms a large, prominent skin lesion,
therapy for phacomatosis pigmentovascularis is rarely discussed. To the best of our knowledge, this is the first
report of phacomatosis pigmentovascularis type II treated with combined laser therapy using Q-switched
alexandrite and long-pulsed dye lasers.
Case presentations: In the first of two cases reported here, a 2-week-old Japanese baby girl was given a diagnosis
of phacomatosis pigmentovascularis type II and Klippel–Trénaunay syndrome because of port-wine stains, cutis
marmorata telangiectatica congenita, and aberrant Mongolian spots over her trunk and limbs. After five laser
therapy sessions under general anesthesia, her aberrant Mongolian spots and port-wine stains have improved. But
interestingly, the cutis marmorata telangiectatica congenita on the patient's back has improved without laser therapy.
In the second case, a 4-month-old Japanese baby boy was referred to us because of port-wine stains, cutis marmorata
telangiectatica congenita, and aberrant Mongolian spots over his face, trunk and limbs. Phacomatosis
pigmentovascularis type II was diagnosed and laser therapy was started. After three laser therapy sessions under
general anesthesia, the aberrant Mongolian spots and port-wine stains have improved. The cutis marmorata
telangiectatica congenita on the baby's back, buttocks, and arms has faded somewhat without laser therapy.
Conclusions: Combined laser therapy improved the phacomatosis pigmentovascularis skin lesions, but was not
effective for the cutis marmorata telangiectatica congenita with hemiatrophy. Cutis marmorata telangiectatica
congenita without atrophy can be expected to improve on its own. Our results will assist physicians considering how
best to treat patients with phacomatosis pigmentovascularis.
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Phacomatosis pigmentovascularis (PPV), a rare congenital
condition, was first reported by Ota et al. in 1947 as a vas-
cular malformation associated with extensive pigmented
nevi [1]. PPV is classified into four types, each of which is
further classified into two subtypes according to whether
there is systemic involvement [2]. Although PPV skin le-
sions are quite large and can be emotionally distressing
for patients and their families, therapy for PPV is rarely
discussed. We here present two patients with PPV type II
who were treated with combined Q-switched alexandrite
laser (QAL) and long-pulsed dye laser (LPDL) therapy.* Correspondence: adachikoji@md.tsukuba.ac.jp
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Case 1
A 2-week-old baby girl born to nonconsanguineous Japa-
nese parents was referred to us because of skin lesions.
The family history and personal history were unremark-
able, and the pregnancy and labor had been uneventful.
The baby's weight and height at birth were in the 50th
percentile. On physical examination, we noted ery-
thematous macules and plaques over her right chest,
abdomen, and arm. We diagnosed these lesions as a
port-wine stain (PWS). We also noted extensive areas
of reddish-blue reticulated, marble-like lesions over her
back and buttocks, consistent with a diagnosis of cutis
marmorata telangiectatica congenita (CMTC). CMTC
with hemihypertrophy was present on her lower right leg.
Bilateral, demarcated greyish-blue hyperpigmentation onLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Adachi et al. Journal of Medical Case Reports 2013, 7:55 Page 2 of 5
http://www.jmedicalcasereports.com/content/7/1/55the buttocks and thighs, partly intermingled with the vas-
cular lesions, was diagnosed as aberrant Mongolian spots.
The rest of the physical examination was normal. Blood
biochemistry, complete blood cell count, chest radiog-
raphy, electrocardiography, and echocardiography were all
within normal limits.
The physical findings indicated a diagnosis of PPV type
IIb and Klippel–Trénaunay syndrome. Laser therapy wasFigure 1 Case 1: A baby with phacomatosis pigmentovascularis type
port-wine stain on her right side, hemihypertrophy of her legs, and cutis m
D) In photographs taken after five sessions of laser therapy, the aberrant M
unchanged. The CMTC on the child's back showed improvement without lstarted when the patient was one-year-old. We used a
QAL (ALEXLASER; Candela Corporation, Wayland, MA,
USA) with an energy density of 6.0J/cm2 to treat the der-
mal melanosis of her buttocks and thighs. An LPDL
(VbeamW; Candela Corporation) with an energy density of
10J/cm2 and 1.5ms was used simultaneously to treat the
PWS and CMTC lesions. Where the lesions were inter-
mingled, we treated the dermal melanosis before the PWSIIb treated with combination laser therapy. (A, B) The baby had a
armorata telangiectatica congenita (CMTC) on her back and legs. (C,
ongolian spots showed improvement, but the CMTC remained mostly
aser therapy.
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sions under general anesthesia. In each session, approxi-
mately 30% of the lesion area was treated; however, her
back has yet to be treated.
The patient is now 3-years-old and shows normal
mental and physical development. Although the hemihy-
pertrophy remains, there is no leg length discrepancy.
The aberrant Mongolian spots have faded. The four au-
thors of this paper evaluated the amount of fading and
agreed that although the lesions are still visible their
color has decreased by about 80%. The PWS on the
patient's trunk and arm has also decreased by about
80%, but the CMTC on her leg is mostly unchanged. We
plan to change the laser power and pulse width for this
patient's future treatment. Of interest, the CMTC on the
patient's back has faded by about 90%, without laser
therapy (Figure 1).Case 2
A 4-month-old baby boy born to nonconsanguineous Jap-
anese parents was referred to us because of skin lesions.
The family history and personal history were unremark-
able, and the pregnancy and labor had been uneventful.
The boy's weight and height at birth were in the 50th per-
centile, and his postnatal development was normal. On
physical examination, we noted a PWS on his right cheek
and CMTC on his right side on his back, buttock, and
arm. We found aberrant Mongolian spots, partly inter-
mingled with the vascular lesions, on his chest and arms.
We also noted ocular pigmentation of his right eye. Oph-
thalmologic examination revealed no other findings. No
atrophy or hypertrophy of the soft tissues was observed.
The rest of the physical examination was normal. Blood
biochemistry, complete blood cell count, chest radiog-
raphy, and electrocardiography were within normal limits.
PPV type IIa was diagnosed, and laser therapy began
when the patient reached one year of age. We used a
QAL with an energy density of 6.0J/cm2 to treat the der-
mal melanosis of his chest and upper limbs. We used an
LPDL with an energy density of 10J/cm2 and 1.5ms to
treat his PWS lesions simultaneously. Where the lesions
were intermingled, we treated the dermal melanosis be-
fore the PWS. The patient underwent three laser therapy
sessions under general anesthesia. We did not treat the
CMTC in any of the sessions.
The boy is now 2-years-old and shows normal mental
and physical development. Both the aberrant Mongolian
spots on his trunk and upper limb and the PWS on his
cheek have decreased by about 60%, although they are
still visible. We plan to treat this patient with another
session of combined laser therapy. The CMTC on the
child's back, buttocks, and arms has faded by about 90%
without laser therapy (Figure 2).Discussion
PPV is classified into the following four types, according
to the epidermal component accompanying the capillary
malformation: type I, nevus flammeus (another term for
PWS) with nevus pigmentosus et verrucosus; type II,
nevus flammeus with aberrant Mongolian spots, with or
without nevus anemicus; type III, nevus flammeus
with nevus spilus or giant speckled lentiginous nevus,
with or without nevus anemicus; and type IV, nevus
flammeus with both aberrant Mongolian spots and speck-
led lentiginous nevus, with or without nevus anemicus [2].
Each type is subdivided as having (a) only oculocutaneous
involvement or (b) extracutaneous features. In addition,
there are reports of patients with CMTC and aberrant
Mongolian spots, and the term PPV type V has been pro-
posed for this condition [3,4].
In 2005, Happle proposed classifying PPV into three
distinct categories [5], descriptively named phacomatosis
cesioflammea, phacomatosis spilorosea, and phacomatosis
cesiomarmorata. Our patients would be classified as
having PPV IIa and IIb in the traditional classification
system, and as having phacomatosis cesioflammea in
the new classification system.
It has been proposed that PPV is the result of non-
allelic twin spotting involving two different recessive mu-
tations [6]. Postzygotic recombination in early embryo-
genesis produces two homozygous daughter cell lines
that migrate to different parts of the body and form a
mosaic pattern of capillary and melanocytic lesions.
PPV has a roughly 50% association rate with systemic
disease in all categories [7]; Klippel–Trénaunay syndrome
and Sturge–Weber syndrome are the most common iden-
tifiable disorders. Case 1 was classified as PPV IIb because
of the presence of nevus flammeus, aberrant Mongolian
spots, and Klippel–Trénaunay syndrome.
Although PPV skin lesions can be distressing for pa-
tients and their families, very few attempts have been
made to treat PPV with laser therapy. Ono and Tateshita
reported an improvement in one case of PPV treated with
a Q-switched ruby laser and a dye laser [8]. Kono et al.
suggested a combined laser approach (a Q-switched ruby
laser, a QAL, and a flashlamp-pumped pulsed-dye laser)
for PPV [9]. It has been reported that aberrant Mongolian
spots can be effectively treated with Q-switched ruby and
alexandrite lasers [10], and that PWS can be treated safely
and effectively with LPDL [11]. Therefore, we used QAL
and LPDL for PPV therapy.
Laser treatment of intermingled vascular and pigmented
lesions can be difficult. Thus, we recommend beginning
PPV therapy with the QAL, followed by the LPDL
after the dermal melanin content has subsided to some
extent [8].
Mazereeuw-Hautier et al. reported that frequency-
doubled Nd:YAG (neodymium-doped yttrium aluminum
Figure 2 Case 2: A baby with phacomatosis pigmentovascularis type IIa treated with combination laser therapy. (A, B) The baby had
aberrant Mongolian spots on his chest and arms, a port-wine stain (PWS) on his cheek, and cutis marmorata telangiectatica congenita (CMTC) on
his lower back and buttocks. (C, D) Photographs taken after three sessions of laser therapy show improvement in the aberrant Mongolian spots
and PWS. The CMTC improved without laser therapy.
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CMTC because of dilated veins and extensive large, deep
capillaries [12]. For the same reason, LPDL therapy was
not effective for our first patient's CMTC with hemi-
atrophy. The power and pulse width will be raised for this
patient's next laser therapy session.
Because CMTC without atrophy can be expected to
improve on its own, vascular lesions should be examinedcarefully to differentiate between PWS and CMTC and
to ascertain whether atrophy is present.
Conclusions
We have reported two cases of PPV type II treated with
combined laser therapy. The combined laser therapy im-
proved the PPV skin lesions, the PWS, and aberrant
Mongolian spots, but was not effective for CMTC with
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http://www.jmedicalcasereports.com/content/7/1/55hemiatrophy. However, CMTC without atrophy can be
expected to improve on its own. To the best of our
knowledge, this is the first report of PPV type II treated
with combined QAL and LPDL laser therapy. Our results
will be of some help to physicians in deciding how best
to treat patients with PPV.
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